TrialScientific reports2018

Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial.

Masaaki Mori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.